What are the risks associated with hormone therapy in transgender patients?
Metadata[+] Show full item record
What are the risks associated with hormone therapy in transgender patients? Evidence-based answer: All-cause mortality is higher in male-to-female (MtF) transgender patients on hormone therapy than untreated males. It is unclear if this difference is due to the hormonal therapy or other factors (HIV/AIDS, illicit drug use, suicide). Hormone therapy for MtF patients is associated with an increased risk of thromboembolic disease, cholelithiasis, hyperprolactinemia, transaminitis, and triglyceride elevations. Masculinizing hormones in female-to-male (FtM) transgender patients are not associated with increased mortality, myocardial infarction (MI), hypertension, or venous thromboembolism (VTE), but are associated with minimal changes in high-density lipoprotein (HDL) cholesterol and systolic blood pressure (BP) (SOR: B, 2 cohort studies and meta-analysis of cohort studies).
Evidence-based practice 20, no. 5 (2017): 03